Ep 33: Manica Balasegaram & the work of GARDP. AMR & patients with cancer. CRISPR-Cas antimicrobials.
Welcome to another month with the AMR Studio! For this occasion, we sat down with Dr. Manica Balasegaram to talk about his path from his years as a physician to his current position as director of the Global Antibiotic Research & Development Partnership (GARDP). Listen to learn how he entered the AMR world and the aspirations and current work done at GARDP. This was such an inspirational interview! In the news section, we talk about a recent review/perspective piece on the current state and challenges of antibiotic resistance in patients with cancer, and we bring you a recent research article looking into the potential of the CRISPR-Cas system as an antimicrobial, and with insight into the potential resistance to it. We hope you enjoy and have a lovely month of October!
You can follow us and subscribe to our podcast to get new episodes directly in your preferred device and platform:
Relevant links:
- Global Antibiotic Research & Development Partnership (GARDP)'s website.
- Manica Balasegaram's profile page.
Further Reading:
- Antibiotic resistance in the patient with cancer: Escalating challenges and paths forward. First article covered in the news.
- Bacterial resistance to CRISPR-Cas antimicrobials. Second article covered in the news.
If you have any comments and suggestions you can email us here, or tweet to us (@UAC_UU) using the hashtag #theAMRStudio.